RG
VRTX icon

Retirement Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Retirement Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$10.4K Sell
25
-1
-4% -$423 ﹤0.01% 466
2023
Q4 		$10.6K Buy
26
+5
+24% +$1.85K ﹤0.01% 438
2023
Q3 		$7.3K Hold
21
– – ﹤0.01% 445
2023
Q2 		$7.39K Buy
21
+5
+31% +$1.69K ﹤0.01% 453
2023
Q1 		$5K Hold
16
– – ﹤0.01% 503
2022
Q4 		$5K Buy
16
+8
+100% +$2.44K ﹤0.01% 444
2022
Q3 		$2K Sell
8
-16
-67% -$4.6K ﹤0.01% 421
2022
Q2 		$7K Buy
24
+8
+50% +$2.14K ﹤0.01% 498
2022
Q1 		$4K Buy
16
+12
+300% +$2.85K ﹤0.01% 576
2021
Q4 		$1K Buy
4
+1
+33% +$194 ﹤0.01% 688
2021
Q3 		$1K Hold
3
– – ﹤0.01% 605
2021
Q2 		$1K Hold
3
– – ﹤0.01% 645
2021
Q1 		$1K Buy
3
+1
+50% +$220 ﹤0.01% 713
2020
Q4 		$0 Buy
2
+1
+100% +$229 ﹤0.01% 743
2020
Q3 		$0 Hold
1
– – ﹤0.01% 724
2020
Q2 		$0 Buy
+1
New +$271 ﹤0.01% 661

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Retirement Group's VRTX Position: Q1 2024 in Review

Retirement Group reduced its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q1 2024, selling an estimated $423 and leaving 25 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #466.

Retirement Group first reported a position in VRTX in Q2 2020 and has held it in 16 quarters since. The position peaked at $10.6K in Q4 2023. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Retirement Group held 25 shares of Vertex Pharmaceuticals worth $10.4K as of Q1 2024.
  • Retirement Group sold 1 Vertex Pharmaceuticals share in Q1 2024, an estimated $423.
  • Vertex Pharmaceuticals made up ﹤0.01% of Retirement Group's portfolio in Q1 2024, its #466 holding.
  • Retirement Group first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 16 quarters since.
  • Retirement Group's Vertex Pharmaceuticals position peaked at $10.6K in Q4 2023.
  • 1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Retirement Group's 13F filing for Q1 2024, filed 30 Apr 2024.